表紙
市場調査レポート

2型糖尿病:パイプライン製品の分析

Type 2 Diabetes - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 232774
出版日 ページ情報 英文 1329 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
2型糖尿病:パイプライン製品の分析 Type 2 Diabetes - Pipeline Review, H1 2016
出版日: 2016年04月27日 ページ情報: 英文 1329 Pages
概要

2型糖尿病は慢性的な症状で、最もよく見られる糖尿病です。血糖値が高いのが特徴で、体がインスリンに対して抵抗したり、十分なインスリンを生成することができなくなります。

当レポートでは、2型糖尿病の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

2型糖尿病の概要

治療薬の開発

2型糖尿病:企業で開発中の治療薬

2型糖尿病:大学/機関で研究中の治療薬

2型糖尿病:パイプライン製品の概況

2型糖尿病:企業で開発中の製品

2型糖尿病:大学/機関で研究中の製品

2型糖尿病の治療薬開発に従事している企業

2型糖尿病:治療薬の評価

薬剤プロファイル

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7682IDB

Summary

Global Markets Direct's, 'Type 2 Diabetes - Pipeline Review, H1 2016', provides an overview of the Type 2 Diabetes pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Type 2 Diabetes, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Type 2 Diabetes
  • The report reviews pipeline therapeutics for Type 2 Diabetes by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Type 2 Diabetes therapeutics and enlists all their major and minor projects
  • The report assesses Type 2 Diabetes therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Type 2 Diabetes

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Type 2 Diabetes
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Type 2 Diabetes pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic porfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Type 2 Diabetes Overview
  • Therapeutics Development
    • Type 2 Diabetes - Therapeutics under Development by Companies
    • Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
    • Type 2 Diabetes - Pipeline Products Glance
    • Type 2 Diabetes - Products under Development by Companies
    • Type 2 Diabetes - Products under Investigation by Universities/Institutes
    • Type 2 Diabetes - Companies Involved in Therapeutics Development
    • Type 2 Diabetes - Therapeutics Assessment
  • Drug Profiles
    • Type 2 Diabetes - Recent Pipeline Updates
    • Type 2 Diabetes - Dormant Projects
    • Type 2 Diabetes - Discontinued Products
    • Type 2 Diabetes - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Type 2 Diabetes, H1 2016
  • Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Development by Companies, H1 2016 (Contd..3)
  • Number of Products under Development by Companies, H1 2016 (Contd..4)
  • Number of Products under Development by Companies, H1 2016 (Contd..5)
  • Number of Products under Development by Companies, H1 2016 (Contd..6)
  • Number of Products under Development by Companies, H1 2016 (Contd..7)
  • Number of Products under Development by Companies, H1 2016 (Contd..8)
  • Number of Products under Development by Companies, H1 2016 (Contd..9)
  • Number of Products under Development by Companies, H1 2016 (Contd..10)
  • Number of Products under Development by Companies, H1 2016 (Contd..11)
  • Number of Products under Development by Companies, H1 2016 (Contd..12)
  • Number of Products under Development by Companies, H1 2016 (Contd..13)
  • Number of Products under Development by Companies, H1 2016 (Contd..14)
  • Number of Products under Development by Companies, H1 2016 (Contd..15)
  • Number of Products under Development by Companies, H1 2016 (Contd..16)
  • Number of Products under Development by Companies, H1 2016 (Contd..17)
  • Number of Products under Development by Companies, H1 2016 (Contd..18)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Development by Companies, H1 2016 (Contd..4)
  • Products under Development by Companies, H1 2016 (Contd..5)
  • Products under Development by Companies, H1 2016 (Contd..6)
  • Products under Development by Companies, H1 2016 (Contd..7)
  • Products under Development by Companies, H1 2016 (Contd..8)
  • Products under Development by Companies, H1 2016 (Contd..9)
  • Products under Development by Companies, H1 2016 (Contd..10)
  • Products under Development by Companies, H1 2016 (Contd..11)
  • Products under Development by Companies, H1 2016 (Contd..12)
  • Products under Development by Companies, H1 2016 (Contd..13)
  • Products under Development by Companies, H1 2016 (Contd..14)
  • Products under Development by Companies, H1 2016 (Contd..15)
  • Products under Development by Companies, H1 2016 (Contd..16)
  • Products under Development by Companies, H1 2016 (Contd..17)
  • Products under Development by Companies, H1 2016 (Contd..18)
  • Products under Development by Companies, H1 2016 (Contd..19)
  • Products under Development by Companies, H1 2016 (Contd..20)
  • Products under Development by Companies, H1 2016 (Contd..21)
  • Products under Development by Companies, H1 2016 (Contd..22)
  • Products under Development by Companies, H1 2016 (Contd..23)
  • Products under Development by Companies, H1 2016 (Contd..24)
  • Products under Development by Companies, H1 2016 (Contd..25)
  • Products under Development by Companies, H1 2016 (Contd..26)
  • Products under Development by Companies, H1 2016 (Contd..27)
  • Products under Development by Companies, H1 2016 (Contd..28)
  • Products under Development by Companies, H1 2016 (Contd..29)
  • Products under Development by Companies, H1 2016 (Contd..30)
  • Products under Development by Companies, H1 2016 (Contd..31)
  • Products under Development by Companies, H1 2016 (Contd..32)
  • Products under Development by Companies, H1 2016 (Contd..33)
  • Products under Development by Companies, H1 2016 (Contd..34)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..4)
  • Products under Investigation by Universities/Institutes, H1 2016 (Contd..5)
  • Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by Adocia, H1 2016
  • Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by AFFiRiS AG, H1 2016
  • Type 2 Diabetes - Pipeline by Alchemia Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Alize Pharma SAS, H1 2016
  • Type 2 Diabetes - Pipeline by AlphaMab Co., Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Ambrx, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Amgen Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by AntriaBio, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Aphios Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by Araim Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by ArisGen SA, H1 2016
  • Type 2 Diabetes - Pipeline by Array BioPharma Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Artery Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H1 2016
  • Type 2 Diabetes - Pipeline by AstraZeneca Plc, H1 2016
  • Type 2 Diabetes - Pipeline by AUS Bio Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Avaxia Biologics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Bayer AG, H1 2016
  • Type 2 Diabetes - Pipeline by Beta-Cell NV, H1 2016
  • Type 2 Diabetes - Pipeline by Betagenon AB, H1 2016
  • Type 2 Diabetes - Pipeline by Biocon Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Biodel Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Biogenomics Limited, H1 2016
  • Type 2 Diabetes - Pipeline by BioLingus AG, H1 2016
  • Type 2 Diabetes - Pipeline by BioRestorative Therapies, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by BioTherapeutics Inc., H1 2016
  • Type 2 Diabetes - Pipeline by BioTime, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H1 2016
  • Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H1 2016
  • Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H1 2016
  • Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Caldan Therapeutics Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Cardax Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H1 2016
  • Type 2 Diabetes - Pipeline by Carmot Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H1 2016
  • Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
  • Type 2 Diabetes - Pipeline by CJ HealthCare Corp., H1 2016
  • Type 2 Diabetes - Pipeline by CohBar, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Corium International, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by CSL Limited, H1 2016
  • Type 2 Diabetes - Pipeline by CureDM, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Dance Biopharm Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Debiopharm International SA , H1 2016
  • Type 2 Diabetes - Pipeline by Delpor, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Diabetica Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by DiaMedica Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by DiscoveryBiomed, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Eisai Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Elcelyx Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Eli Lilly and Company, H1 2016
  • Type 2 Diabetes - Pipeline by enGene, Inc, H1 2016
  • Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Eternygen GmbH, H1 2016
  • Type 2 Diabetes - Pipeline by Euroscreen S.A., H1 2016
  • Type 2 Diabetes - Pipeline by Evotec AG, H1 2016
  • Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by FibroStatin SL, H1 2016
  • Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H1 2016
  • Type 2 Diabetes - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by Genfit SA, H1 2016
  • Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H1 2016
  • Type 2 Diabetes - Pipeline by Gero Corp, H1 2016
  • Type 2 Diabetes - Pipeline by Geropharm, H1 2016
  • Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Glucox Biotech AB, H1 2016
  • Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H1 2016
  • Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by Halozyme Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by HanAll Biopharma Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Handok Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Heptares Therapeutics Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Hua Medicine Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Immuron Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Innopharmax Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Integral Molecular, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by IntelliCell BioSciences Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Intrexon Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by IPCA Laboratories Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Islet Sciences, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by iTherX, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by JHL Biotech, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Johnson & Johnson, H1 2016
  • Type 2 Diabetes - Pipeline by Kadimastem Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Kadmon Corporation, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Kareus Therapeutics, SA, H1 2016
  • Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by LG Life Science LTD., H1 2016
  • Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Lonestar Heart, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Longevity Biotech, Inc, H1 2016
  • Type 2 Diabetes - Pipeline by Magnus Life Science, H1 2016
  • Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H1 2016
  • Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H1 2016
  • Type 2 Diabetes - Pipeline by MedImmune, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Mellitech SAS, H1 2016
  • Type 2 Diabetes - Pipeline by Merck & Co., Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Mesoblast Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Metabolic Solutions Development Company, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Metabolys SAS, H1 2016
  • Type 2 Diabetes - Pipeline by MI.TO. Technology S.r.L., H1 2016
  • Type 2 Diabetes - Pipeline by MicroBiome Therapeutics LLC, H1 2016
  • Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H1 2016
  • Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by Naia Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Neurimmune Holding AG, H1 2016
  • Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Nimbus Therapeutics, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by NOD Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Nordic Bioscience A/S, H1 2016
  • Type 2 Diabetes - Pipeline by Novartis AG, H1 2016
  • Type 2 Diabetes - Pipeline by NovaTarg Therapeutics, Inc, H1 2016
  • Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H1 2016
  • Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H1 2016
  • Type 2 Diabetes - Pipeline by Omeros Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by OPKO Health, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Orbis Biosciences, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016
  • Type 2 Diabetes - Pipeline by Peptron, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Pfizer Inc., H1 2016
  • Type 2 Diabetes - Pipeline by PharmaIN Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Pivot Pharmaceuticals Inc, H1 2016
  • Type 2 Diabetes - Pipeline by Poxel SA, H1 2016
  • Type 2 Diabetes - Pipeline by Progen Pharmaceuticals Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Prometheon Pharma, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by ProMetic Life Sciences Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Prothena Corporation Plc, H1 2016
  • Type 2 Diabetes - Pipeline by Purzer Pharmaceutical Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Reata Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Red Glead Discovery AB, H1 2016
  • Type 2 Diabetes - Pipeline by RegenMedTX, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by reMYND NV, H1 2016
  • Type 2 Diabetes - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016
  • Type 2 Diabetes - Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Saniona AB, H1 2016
  • Type 2 Diabetes - Pipeline by Sanofi, H1 2016
  • Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by SATT Conectus Alsace SAS, H1 2016
  • Type 2 Diabetes - Pipeline by SBI Pharmaceuticals Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Seres Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Serodus ASA, H1 2016
  • Type 2 Diabetes - Pipeline by Serometrix, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Sevion Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Shanghai Fosun Pharmaceutical (Group) Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Shanghai Pharmaceutical Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Shantani Proteome Analytics Pvt. Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Shionogi & Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016 327Type 2 Diabetes - Pipeline by Sirona Biochem Corp, H1 2016
  • Type 2 Diabetes - Pipeline by SJT Molecular Research, S.L. , H1 2016
  • Type 2 Diabetes - Pipeline by SK Chemicals Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Sprint Bioscience AB, H1 2016
  • Type 2 Diabetes - Pipeline by Starpharma Holdings Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Stelic Institute & Co., Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Strongbridge Biopharma plc , H1 2016
  • Type 2 Diabetes - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Teijin Pharma Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Theracos, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Therapix Biosciences Ltd, H1 2016
  • Type 2 Diabetes - Pipeline by Thermalin Diabetes, LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Thetis Pharmaceuticals LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Toray Industries, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Torrent Pharmaceuticals Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Transgene Biotek Limited, H1 2016
  • Type 2 Diabetes - Pipeline by TWi Pharmaceuticals, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Uni-Bio Science Group Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Vicore Pharma AB, H1 2016
  • Type 2 Diabetes - Pipeline by Viking Therapeutics, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Virobay Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Vivus, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by vTv Therapeutics LLC, H1 2016
  • Type 2 Diabetes - Pipeline by Vybion, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by XBiotech USA, Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
  • Type 2 Diabetes - Pipeline by Xizang Haisco Pharmaceutical Group Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by XL-protein GmbH, H1 2016
  • Type 2 Diabetes - Pipeline by XOMA Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by Yuhan Corporation, H1 2016
  • Type 2 Diabetes - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Zafgen Inc., H1 2016
  • Type 2 Diabetes - Pipeline by Zealand Pharma A/S, H1 2016
  • Type 2 Diabetes - Pipeline by Zensun (Shanghai) Sci & Tech Co., Ltd., H1 2016
  • Type 2 Diabetes - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Type 2 Diabetes Therapeutics - Recent Pipeline Updates, H1 2016
  • Type 2 Diabetes - Dormant Projects, H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..1), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..2), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..3), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..4), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..5), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..6), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..7), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..8), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..9), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..10), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..11), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..12), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..13), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..14), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..15), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..16), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..17), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..18), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..19), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..20), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..21), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..22), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..23), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..24), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..25), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..26), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..27), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..28), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..29), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..30), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..31), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..32), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..33), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..34), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..35), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..36), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..37), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..38), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..39), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..40), H1 2016
  • Type 2 Diabetes - Dormant Projects (Contd..41), H1 2016
  • Type 2 Diabetes - Discontinued Products, H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..1), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..2), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..3), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..4), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..5), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..6), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..7), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..8), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..9), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..10), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..11), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..12), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..13), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..14), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..15), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..16), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..17), H1 2016
  • Type 2 Diabetes - Discontinued Products (Contd..18), H1 2016

List of Figures

  • Number of Products under Development for Type 2 Diabetes, H1 2016
  • Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Top 10 Routes of Administration, H1 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top